Advancedadvanced biology

Blood Coagulation: The Clotting Cascade

Learning objectives

  • Distinguish the extrinsic (tissue factor), intrinsic (contact), and common pathways.
  • Explain how tenase and prothrombinase complexes assemble on phospholipid surfaces.
  • Trace thrombin's multiple roles: fibrin formation, platelet activation, feedback.
  • Evaluate natural anticoagulants: TFPI, antithrombin, protein C.
  • Relate cascade defects and brakes to hemophilia, thrombosis, and fibrinolysis.

Injury exposes the trigger

Coagulation begins with exposure: damage to a vessel wall exposes tissue factor, a membrane protein normally sequestered from blood, to circulating factor VII. The tissue factor-VIIa complex -- the extrinsic tenase -- activates factors IX and X, launching the cascade. (The 'intrinsic' or contact pathway, initiated when factor XII meets negatively charged surfaces, contributes little to normal hemostasis in vivo -- factor XII-deficient people do not bleed -- though it matters in pathological thrombosis and is what the aPTT lab test measures.) The cascade's architecture is a series of zymogen activations: each activated protease (denoted 'a') cleaves and activates the next, so a small initiating signal is amplified enormously -- one molecule of activated factor can generate thousands downstream. Vitamin K is the quiet cofactor of the whole system: it enables gamma-carboxylation of glutamate residues on factors II, VII, IX, and X (plus proteins C and S), giving them the calcium-binding Gla domains that anchor them to phospholipid surfaces -- which is why warfarin, a vitamin K antagonist, is an anticoagulant.

Complexes on membranes: tenase and prothrombinase

The cascade's proteases work inefficiently in solution -- they become formidable only when assembled into membrane-bound complexes. The intrinsic tenase (VIIIa-IXa) and the prothrombinase complex (Va-Xa) form on negatively charged phospholipid surfaces, principally phosphatidylserine exposed on activated platelets. Assembly accelerates the reactions by orders of magnitude: prothrombinase converts prothrombin (factor II) to thrombin roughly 300,000 times faster than factor Xa alone. This surface dependence is a localization strategy -- explosive thrombin generation happens on the platelet plug at the injury site, not freely in plasma. The cofactors Va and VIIIa are themselves activated by thrombin, creating positive feedback: the first traces of thrombin massively upregulate their own production machinery. Hemophilia A and B -- deficiencies of factors VIII and IX -- are failures of the intrinsic tenase: without it, the amplification needed for a stable clot never develops, though initiation via tissue factor still occurs -- explaining why hemophiliacs form fragile initial clots that fail.

Thrombin: the cascade's executive

Thrombin (factor IIa) is the central effector, and its job list is long. It cleaves fibrinogen -- a soluble plasma protein -- releasing fibrinopeptides A and B and exposing polymerization sites; the resulting fibrin monomers assemble into protofibrils, then fibers, then a three-dimensional mesh. Factor XIIIa (also thrombin-activated) crosslinks the fibers covalently, stabilizing the clot. Thrombin simultaneously activates platelets through PAR (protease-activated) receptors, recruits more platelets, activates cofactors V and VIII (positive feedback), and activates TAFI, which protects the clot from premature lysis. One protease thus coordinates the entire hemostatic response: building the mesh, recruiting the cellular plug, amplifying itself, and defending the product. The thrombin burst -- the explosive, localized generation of thrombin on the platelet surface -- is the point of the whole cascade; everything upstream exists to produce it rapidly, locally, and in sufficient quantity, and everything downstream exists to regulate it.

The brakes: confining the clot

A cascade that amplifies must be contained, or every nick would clot the circulation. Three anticoagulant systems provide the brakes. TFPI (tissue factor pathway inhibitor) shuts down the initiating tissue factor-VIIa-Xa complex -- limiting initiation. Antithrombin, a serpin, irreversibly inhibits thrombin and factors Xa, IXa (heparin accelerates it ~1000-fold, which is heparin's mechanism). The protein C system provides the elegant feedback: thrombin, bound to endothelial thrombomodulin, switches from procoagulant to anticoagulant -- activating protein C, which with its cofactor protein S degrades factors Va and VIIIa, dismantling the tenase and prothrombinase complexes. Factor V Leiden -- the most common inherited thrombophilia -- is a mutation making factor Va resistant to protein C cleavage: the brake fails, and clotting risk rises. The endothelium itself is anticoagulant at rest (producing prostacyclin, nitric oxide, expressing thrombomodulin and heparan sulfate) and becomes procoagulant only when injured -- hemostasis as a property of the vessel wall, not just the plasma.

Dissolving the clot: fibrinolysis

Once the vessel heals, the clot must go. Fibrinolysis is driven by plasmin, generated from plasminogen by tissue plasminogen activator (tPA, released by endothelium) and urokinase; plasmin cleaves fibrin into degradation products (including D-dimer, the clinical marker of active clotting-and-lysis). The system is itself regulated: PAI-1 inhibits tPA, alpha2-antiplasmin inhibits plasmin, and TAFI (thrombin-activated, from the coagulation side) trims fibrin's C-terminal lysines to reduce plasminogen binding -- crosstalk ensuring lysis follows hemostasis, not precedes it. Therapeutic thrombolysis exploits this: recombinant tPA dissolves the occluding clot in ischemic stroke and myocardial infarction, effective only within hours because older clots organize and resist lysis. The balance between coagulation and fibrinolysis is continuous and dynamic -- thrombosis is coagulation winning in the wrong place, bleeding is it losing in the right place, and every anticoagulant and procoagulant drug is an attempt to move the fulcrum deliberately.

Amplification plus localization

Each protease activates many of the next (amplification), but the key complexes assemble only on activated-platelet phospholipid (localization). The cascade is an explosive that detonates only where the platelet plug marks the spot.

Key points

  • Extrinsic initiation (tissue factor-VIIa) drives physiology; the contact (intrinsic) pathway matters pathologically and in the aPTT assay.
  • Tenase (VIIIa-IXa) and prothrombinase (Va-Xa) complexes on platelet phospholipid accelerate their reactions by orders of magnitude -- localization plus amplification.
  • Thrombin cleaves fibrinogen to fibrin, activates platelets (PARs), cofactors V/VIII (feedback), and factor XIIIa (crosslinking).
  • Brakes: TFPI (initiation), antithrombin (thrombin/Xa; heparin-accelerated), protein C/S (degrades Va/VIIIa; thrombin-thrombomodulin switches thrombin anticoagulant).
  • Factor V Leiden resists protein C -- the commonest inherited thrombophilia; hemophilia A/B are intrinsic-tenase failures.
  • Fibrinolysis (tPA -> plasmin -> D-dimer) dissolves healed clots; therapeutic tPA works only on fresh occlusions.

Common misconceptions

✗ Myth: The intrinsic pathway initiates normal clotting.

✓ Truth: Tissue factor (extrinsic) initiates physiology; factor XII-deficient people don't bleed abnormally. The intrinsic pathway matters in pathological thrombosis and lab testing.

✗ Myth: Warfarin thins the blood.

✓ Truth: Warfarin blocks vitamin K-dependent gamma-carboxylation of factors II, VII, IX, X (and proteins C/S), preventing their membrane anchoring -- it impairs clotting factor function, not blood viscosity.

✗ Myth: Clots dissolve on their own without a system.

✓ Truth: Fibrinolysis is an active, regulated cascade (tPA-plasmin, balanced by PAI-1 and alpha2-antiplasmin) -- dissolution is as controlled as formation.

Frequently asked questions

What starts clotting after an injury?

Exposed tissue factor binds factor VIIa, forming the extrinsic tenase that activates factors IX and X -- launching the amplifying protease cascade at the injury site.

Why do tenase and prothrombinase need platelet surfaces?

Assembly on phosphatidylserine-rich activated-platelet membranes accelerates the reactions enormously (prothrombinase ~300,000-fold) -- confining explosive thrombin generation to the injury site.

What does thrombin do besides making fibrin?

It activates platelets via PAR receptors, activates cofactors V and VIII (positive feedback), activates factor XIIIa to crosslink fibrin, and -- bound to thrombomodulin -- activates protein C (negative feedback).

What is hemophilia at the molecular level?

Hemophilia A (factor VIII) and B (factor IX) disable the intrinsic tenase, crippling the amplification needed for stable clots -- initiation occurs but the clot fails.

How does heparin work?

It accelerates antithrombin ~1000-fold; antithrombin then irreversibly inhibits thrombin and factor Xa (and IXa) -- braking the cascade's key proteases.